General description

A cell-permeable triaminotriazine ROCK inhibitor (IC₅₀ = 6 nM in a cell-free ROCK1 kinase assay) that affects 24 other commonly studied non-ROCK kinases only at much higher concentrations (IC₅₀ >2 µM) and effectively blocks MCP-1-induced THP-1 cell migration (IC₅₀ = 30 nM) in vitro. Subcutaneous injection (3-10 mg/kg) of ROCK Inhibitor VII and oral dosing (30 mg/kg) of Y-27632 (Cat. Nos. 688000 & 688001) are both reported to significantly reduce arterial blood pressure in a spontaneous hypertensive rat model in vivo.

A cell-permeable triaminotriazine ROCK inhibitor (IC₅₀ = 6 nM in a cell-free ROCK1 kinase assay) that affects 24 other commonly studied non-ROCK kinases only at much higher concentrations (IC₅₀ >2 µM) and effectively blocks MCP-1-induced THP-1 cell migration (IC₅₀ = 30 nM) in vitro. Subcutaneous injection (3-10 mg/kg) of ROCK Inhibitor VII and oral dosing (30 mg/kg) of Y-27632 (Cat. Nos. 688000 & 688001) are both reported to significantly reduce arterial blood pressure in a spontaneous hypertensive rat model in vivo.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Ho, K.K., et al. 2009. Bioorg. Med. Chem. Lett.19, 6027.

Packaging

Packaged under inert gas

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Standard Handling (A)